Molecular handedness: Impact on the development of chiral drugs

Indian Drugs

Volumn 35, Issue 7, 1998, Pages 446-457

  Valliappan, K ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Biological actions; Chiral drugs; Chiral recognition; Handedness; Pharmacodynamic; Racemic switch; Stereospecific

Indexed keywords

DRUG;

CHIRALITY; DRUG RESEARCH; DRUG STRUCTURE; REVIEW; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

EID: 0031816106     PISSN: 0019462X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Bassindale, A., The Third Dimension in Organic Chemistry, Wiley, New York, 1984.
2. Cahn, R. S., Ingold, C. K., and Prelog, V., Experentia, 1956, 12, 81-88.
3. Mislow, K., & Siegel, J., J.Am. Chem. Soc., 1984, 106, 3319-3328.
4. Valliappan, K., Indian Drugs, 1996, 33(3), 96-106.
5. Seymour, M., Pharm. J., 1990, 224, 25-29.
6. Simonyi, M., Med. Res. Rev., 1984, 4, 359-413.
7. Jamali, F., Mehvar, R., & F. M. Pasutto., J. Pharm. Sci., 1989, 78, 695-715.
8. Drayer, D. F., Clin. Pharmacol. Ther., 1986, 40, 125-133.
9. Williams, K. M., Advances in Pharmacology, 1991, 22, 57-134.
10. Crossely, R. Tetrahedron, 1992, 48, 8155-8178.
11. Gross, M.,Ann. Rep. Med. Chem., 1990,25,323-331.
12. Scott, A, K., Drug Ind. J., 1990, 24, 121-123.
13. Wainer, I.W., & Drayer, D. E., Eds.,Drug Stereochemistry and Pharmacology: Marcel-Dekker, New York, 1988.
14. Smith, D. F., CRC Hand book of stereoisomeric Drugs in Psychotherapy, CRC Boca Ratan, 1984.
15. Lehman, F. P. A., Trends Pharmacol. Sci., 1986, 7, 281-285.
16. Smith, R.L., & Caldwell., Trends Pharmacol. Sci., 1988, 9, 75-77.
17. Ariens, E. J., in Chirality in Drug Design and Synthesis (Ed. C. Brown) Academic Press, New York, 1990, 29-43.
18. Fassihi, A. R., Int. J. Pharm., 1993, 92, 1-14.
19. Tomaszewski, J., & Rumore, M. M.,Drug Dev. Ind. pharm., 1994, 20(2), 119-139.
20. Eliel, E. L., and Wilen, S. H., Stereochemistry of Organic Compounds, John Wiley & Sons, 1994, 201-214.
21. Decamp, W. H., J. Pharm. Biomed. Anal., 1993, 11, 1167-1172.
22. Holmes, Jr., Baum, Bernner, Eaton, Gross, Grundfest, Margeson, Morton, Murphy, Palling, Simon & Stoll, Pharmaceutical Technology, May 1990.
23. William, K., & Lee, E., Drugs, 1986, 30, 333-354
24. Borman, S., Chem. Eng. News, 1990, 7, 9-14.
25. Caldwell, J., Chem. & Ind., 1995, 8, 176-179
26. Allenmark, S., Acta Pharm. Nord., 1990, 2, 161-170.
27. Wainer, I. W., Am. J. Hosp. Pharm., 1992, 49, Suppl. 1, S4-S8.
28. Ariens, E. J., Med. Res. Rev., 1986, 6, 451-466.
29. De Camp, W., Remarks Delivered to the World Pharmacy Congress, Wahington, D. C., 1991, Sept. 6, 1-19.
30. Decamp, W., Chirality 1989, 1, 2-6.
31. Weissinger, J., Drug Inf. J., 1989, 23,663-667.
32. Gross, M., Reg. Affairs J., 1991, 3, 483-494
33. Smith D. F., Pharmacol. Toxicol., 1989, 65, 321-330.
34. Areins, E. J, Van Rensen, J.J.S, & Welling, W., Stereoselectivity of Pesticides, biological and chemical Problems, Elsvier, Amsterdam, 1988.
35. Testa, B., in'New Trends in Phamacokinetics', (Eds A. Rescigno & A. K. Thakur) Plenum Press, New York, 1991, 257-269.
36. Marzo. A., Drug Res., 1994, 44-1, 791-793.
37. Carey, J., Chem. Bri., 1993, 12, 1053-1057.
38. Tucker, G, T., Acta Pharm. Nord., 1990, 2, 193-196.
39. Caldwell, J., J. Chromatogr. A, 1996, 719, 3-13.
40. Waldeck, B., Chirality, 1993, 5, 350-355.
41. Campbell, D. B., Acta Pharm. Nord., 1990, 2, 217-226
42. Sheldon, R., Chem. & Ind., 1990, 4, 212-219.
43. Crom, W,R. Am. J. Hosp. Pharm., 1992, 49, suppl. 1, S9-S14.
44. Wright, M. R., and Jamali, F., Journal of Pharmacological & Toxicological Methods, 1993, 29, 1-9.
45. Brown, M. J., & Davies, S. G., Nature, 1989, 342, 631-636.
46. Areins, E. J., Wuis, E., Veriga, W. J.,Biochem. Pharmacol., 1988, 37, 9-18.
47. Ariens, E. J., & Simonis, A, N., in 'Strategy in Drug Research' (ed. J. A. Keveling Buisman), Elsevier Scientific Company, New York, 1982, 165-167.
48. Ariens, E. J., Eur. J. Clin. Pharmacol. Ther., 1984, 26, 663-668
49. Ariens, E. J., Med. Res. Rev., 1987, 7, 367-387.
50. Ariens, E. J., Med. Res. Rev., 1988, 8, 309-320.
51. Ariens, E. J., Clin. Pharmacol.Ther., 1987, 21, 827-829.
52. Ariens, E. J., Drug Intell. Clin. Pharm., 1987, 22, 827-829.
53. Ariens, E. J., Pharmacol. Toxicol. Sci., 1989, 64, 319-320.
54. Ariens, E. J.,Trends Pharmacol. Sci., 1986, 7, 200-205.
55. Pfeiffer, C.C., Science, 1956, 124, 29-31.
56. Testa, B., Acta Pharm. Nord., 1990, 2, 137-144.
57. Testa, B., in 'Chirality & Biological Activity', (Eds. B. Holmstedts, B. Testa & H. Frank), New York, Alan R, Liss Inc, 1990, 15-32.
58. Fedresel, H. J., CHEMTECH., 1993, 23, 24-33.
59. Fedresel, H. J., Endeavour, 1994, 18, 164-172.
60. Hutt, A. J., & Caldwell, J., J. Clin. Pharmacokin., 1984, 9, 371-373.
61. Ehrlich, G. E., Am. J. Hosp. Pharm., 1992, 49, S1-S18.
62. Cayen, M, N., Chirality, 1991, 3, 94-98.
63. Testa, B., Trends Pharmacol. Sci., 1986, 7, 60-64.
64. Testa, B., & Trager, W. F., Chirality, 1990, 2, 129-133.
65. Walle, T., and Walle, Y. K., Trends Pharmacol. Sci., 1986, 7, 155-158.
66. Evans, A. M., Nation, R. L., Sansom, L. N., Bochner, F., & Somogyi, A. A., Br. J. Clin. Pharmacol., 1988, 26, 771-780.
67. Testa, B., Carrupt, P., & Gal, J., Chirality, 1993, 5, 106.
68. Stinson, S. C., Chem. Eng. News, 1993, 8, 38-64.
69. Stinson, S. C., Chem,. Eng. News, 1995, 10, 44-74.
70. Millership, J., & Fitzpatrick, A., Chirality, 1993, 5, 573-576.
71. Mason, S., Trends Pharmacol. Sci., 1982, 7, 20-23.
72. Hegstrom, R. A., & Kondapudi, D. K., Scientific American, 1990, 1, 108-115.
73. Ponnamperuma, C., & Mac Dermoff, A. J., Chem. Bri., 1994, 20, 119-139.